Relay Therapeutics Inc (RLAY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Relay Therapeutics Inc (RLAY) has a cash flow conversion efficiency ratio of -0.080x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-51.11 Million) by net assets ($642.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Relay Therapeutics Inc for the company's overall valuation and market capitalisation.
Relay Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Relay Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Relay Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Relay Therapeutics Inc ranked by their cash flow conversion efficiency. Explore Relay Therapeutics Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Treasury Wine Estates Ltd
AU:TWE
|
0.030x |
|
Ningbo Sanxing Medical Electric Co Ltd
SHG:601567
|
0.043x |
|
ASPEN PHAR.UN.ADR /1 O.N.
F:LDZU
|
N/A |
|
National HealthCare Corporation
NYSE MKT:NHC
|
0.058x |
|
ROCKWOOL International A/S
CO:ROCK-A
|
0.012x |
|
Quilter PLC
JSE:QLT
|
0.318x |
|
Orion Oyj A
HE:ORNAV
|
0.086x |
|
First BanCorp
F:OLWN
|
0.072x |
Annual Cash Flow Conversion Efficiency for Relay Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Relay Therapeutics Inc from 2018 to 2025. View today's stock price for Relay Therapeutics Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $567.06 Million | $-235.46 Million | -0.415x | -29.65% |
| 2024-12-31 | $777.79 Million | $-249.11 Million | -0.320x | +19.80% |
| 2023-12-31 | $752.00 Million | $-300.32 Million | -0.399x | -65.36% |
| 2022-12-31 | $950.22 Million | $-229.49 Million | -0.242x | -191.42% |
| 2021-12-31 | $897.81 Million | $-74.41 Million | -0.083x | +38.28% |
| 2020-12-31 | $763.29 Million | $-102.49 Million | -0.134x | -136.63% |
| 2019-12-31 | $-180.44 Million | $-66.13 Million | 0.367x | -7.88% |
| 2018-12-31 | $-110.93 Million | $-44.13 Million | 0.398x | -- |
About Relay Therapeutics Inc
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clin… Read more